A new era of genetic engineering for autoimmune and inflammatory diseases

Ewart, Dave; Peterson, Erik; Steer, Clifford J.

doi:10.1016/j.semarthrit.2019.05.004

Cited by 10 publications

(6 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A drug delivery system is a technical system that comprehensively regulates the distribution of drugs in a living body in terms of delivery space, time, and dosage [149]. The goal is to deliver the right amount of the drug to the right place at the right time, increasing drug bioavailability and reducing costs and side effects [150]. A drug delivery system is a fusion of medicine, engineering (materials, mechanics, and electronics), and pharmacy.…”

Section: Application Of Chitosan Derivative Nanoparticles In Drug Delmentioning

confidence: 99%

Chitosan Derivatives and Their Application in Biomedicine

Wang

Meng

et al. 2020

IJMS

651

326

View full text Add to dashboard Cite

Chitosan is a product of the deacetylation of chitin, which is widely found in nature. Chitosan is insoluble in water and most organic solvents, which seriously limits both its application scope and applicable fields. However, chitosan contains active functional groups that are liable to chemical reactions; thus, chitosan derivatives can be obtained through the chemical modification of chitosan. The modification of chitosan has been an important aspect of chitosan research, showing a better solubility, pH-sensitive targeting, an increased number of delivery systems, etc. This review summarizes the modification of chitosan by acylation, carboxylation, alkylation, and quaternization in order to improve the water solubility, pH sensitivity, and the targeting of chitosan derivatives. The applications of chitosan derivatives in the antibacterial, sustained slowly release, targeting, and delivery system fields are also described. Chitosan derivatives will have a large impact and show potential in biomedicine for the development of drugs in future.

show abstract

Section: Application Of Chitosan Derivative Nanoparticles In Drug Delmentioning

confidence: 99%

Chitosan Derivatives and Their Application in Biomedicine

Wang

Meng

et al. 2020

IJMS

651

326

View full text Add to dashboard Cite

show abstract

“…Experience is supporting use of RIC regimens, and preferring a healthy matched unrelated donor over family members and/or matched unrelated umbilical cord donors when the disease-causing gene mutation is unknown [16 ▪▪ ,17,154–155,156 ▪▪ ]. Other cell-based therapies such as mesenchymal stromal cells and gene editing and/or therapy for monogenic disorders are promising new breakthroughs [94,157,158]. Addressing the need for extended, prospective clinical trials of HSCT against biologic therapies, and the challenges of significant disease relapse rate and high transplant-related morbidity and mortality are likely to determine the future role of HSCT in the treatment of paediatric rheumatic diseases [22 ▪▪ ,159].…”

Section: Discussionmentioning

confidence: 99%

Haematopoietic stem cell transplantation in paediatric rheumatic disease

Abinun

Slatter

2021

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of reviewA small proportion of children affected by rheumatic diseases suffer from severe, progressive disease, resistant to conventional antirheumatic therapies and to biologic agents interfering with inflammatory cytokines, costimulatory molecules expressed on immune system cells and intracellular signalling pathways. Adding to the poor prognosis is a high risk from significant morbidity and mortality associated with longterm treatment with multiple, often combined anti-inflammatory and immunosuppressive agents. Carefully selected patients from this unfortunate group may benefit from treatment with haematopoietic stem cell transplantation. Recent findingsThe majority of patients with severe paediatric rheumatic and autoinflammatory diseases treated with autologous and/or allogeneic haematopoietic stem cell transplantation achieved long-term remission. However, the incidence of disease relapse and transplant related morbidity and mortality is still significant. SummaryCareful patient and donor selection, timing of the transplant earlier in the course of disease rather than the 'last resort' and choosing the most suitable conditioning regimen for each individual patient are the major factors favouring successful outcome. Close co-operation between the patients, their family, and involved medical teams is essential. Keywords auto-inflammatory diseases, complete remission, disease relapse, haematopoietic stem cell transplantation, paediatric rheumatic diseases, transplant-related mortality && ]. For such children, the only treatment option is haematopoietic stem cell transplantation (HSCT), often referred to as the 'last resort' or 'salvage' therapy [12,13].

show abstract

“…It is still a challenge for human to overcome inflammatory disease which due to invading of exogenous pathogens, trauma and some unknown reason, particularly some widespread chronic diseases such as Alzheimer [33,34]. Developing more effective and less toxic drugs to treat inflammatory diseases is extremely urgent.…”

Section: Discussionmentioning

confidence: 99%

P22077 inhibits LPS-induced inflammatory response by promoting K48-linked ubiquitination and degradation of TRAF6

Zhao

et al. 2020

Aging

View full text Add to dashboard Cite

Inflammation is a biological process associated with multiple human disorders such as autoimmune diseases and metabolic diseases. Therefore, alleviation of inflammation is important for disease prevention or treatment. Recently, deubiquitinating enzymes (DUBs), especially ubiquitin specific protease-7 (USP7) attracts increasing attention as a potential drug target for inflammation. As an inhibitor of USP7, P22077 has been used to study the roles of USP7 in inflammatory response and neuroblastoma growth. However, the role and precise mechanism of P22077 in anti-inflammatory is still indistinct. In this study, we demonstrated that P22077 could attenuate the release of pro-inflammatory factors including TNF-α, IL-1β, IL-6 and NO, suppress mRNA expression of COX-2 and iNOS, and inhibit activation of NF-κB and MAPKs signaling pathways in Raw264.7 cells and mouse peritoneal macrophages after LPS stimulation. In vivo study showed that P22077 could relieve inflammatory response and reduce the lung injury in C57BL/6 mice with LPS-induced endotoxemia. Mechanically, P22077 might play an anti-inflammatory role by promoting tumor necrosis factor receptorassociated factor 6 (TRAF6) degradation via K48-linked polyubiquitination. These findings provide a rationale for the role of the P22077 in anti-inflammatory pathway and the promising clinical application of P22077 to treat inflammatory diseases.

show abstract

A new era of genetic engineering for autoimmune and inflammatory diseases

Cited by 10 publications

References 52 publications

Chitosan Derivatives and Their Application in Biomedicine

Chitosan Derivatives and Their Application in Biomedicine

Haematopoietic stem cell transplantation in paediatric rheumatic disease

P22077 inhibits LPS-induced inflammatory response by promoting K48-linked ubiquitination and degradation of TRAF6

Contact Info

Product

Resources

About